Search
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective d...
Categories: Purinergic P1 Receptor AgonistsIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesInsulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigational[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation. … [A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersTecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Categories: Purinergic P1 Receptor AgonistsMUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalDendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions.
Ormeloxifene
go.drugbank.com/drugs/DB13310Experimental[A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) and d-isomers (d-ormeloxifene) of _trans_-ormeloxifene. … [A251475] The use of levormeloxifene for the treatment of reduced bone turnover and the prevention of atherosclerosis has been evaluated; however, drug development was discontinued due to adverse events
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalSeveral different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEstradiol acetate
go.drugbank.com/drugs/DB13952ApprovedVet approvedEstradiol acetate is commercially available as Femring, a vaginal ring used for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A1 Substrates